JP2003508028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508028A5 JP2003508028A5 JP2001513995A JP2001513995A JP2003508028A5 JP 2003508028 A5 JP2003508028 A5 JP 2003508028A5 JP 2001513995 A JP2001513995 A JP 2001513995A JP 2001513995 A JP2001513995 A JP 2001513995A JP 2003508028 A5 JP2003508028 A5 JP 2003508028A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- antibody
- adam8
- agent
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 description 15
- 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 description 9
- 101000832767 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 8 Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14621799P | 1999-07-28 | 1999-07-28 | |
| US60/146,217 | 1999-07-28 | ||
| PCT/US2000/020731 WO2001009189A2 (en) | 1999-07-28 | 2000-07-27 | Compositions and methods for the treatment of tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011231764A Division JP5897300B2 (ja) | 1999-07-28 | 2011-10-21 | 腫瘍治療のための組成物と方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508028A JP2003508028A (ja) | 2003-03-04 |
| JP2003508028A5 true JP2003508028A5 (enExample) | 2007-10-04 |
Family
ID=22516336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513995A Withdrawn JP2003508028A (ja) | 1999-07-28 | 2000-07-27 | 腫瘍治療のための組成物と方法 |
| JP2011231764A Expired - Lifetime JP5897300B2 (ja) | 1999-07-28 | 2011-10-21 | 腫瘍治療のための組成物と方法 |
| JP2014040627A Pending JP2014144959A (ja) | 1999-07-28 | 2014-03-03 | 腫瘍治療のための組成物と方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011231764A Expired - Lifetime JP5897300B2 (ja) | 1999-07-28 | 2011-10-21 | 腫瘍治療のための組成物と方法 |
| JP2014040627A Pending JP2014144959A (ja) | 1999-07-28 | 2014-03-03 | 腫瘍治療のための組成物と方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7226596B2 (enExample) |
| EP (1) | EP1204682B1 (enExample) |
| JP (3) | JP2003508028A (enExample) |
| AT (1) | ATE488529T1 (enExample) |
| AU (1) | AU776600B2 (enExample) |
| CA (1) | CA2378182C (enExample) |
| DE (1) | DE60045247D1 (enExample) |
| ES (1) | ES2355055T3 (enExample) |
| WO (1) | WO2001009189A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE488529T1 (de) * | 1999-07-28 | 2010-12-15 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| JPWO2003070936A1 (ja) | 2002-02-20 | 2005-06-09 | 山之内製薬株式会社 | 新規ポリペプチド |
| WO2005090991A1 (en) * | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Adam8 as tumor marker and therapeutic target for non-small cell lung cancer |
| CN1705753A (zh) * | 2002-09-30 | 2005-12-07 | 肿瘤疗法科学股份有限公司 | 非小细胞肺癌的诊断方法 |
| US20080014594A1 (en) * | 2003-01-31 | 2008-01-17 | Kevin Hestir | Lung-Expressed Polypeptides |
| US7595040B2 (en) * | 2004-11-10 | 2009-09-29 | Novartis Vaccines And Diagnostics, Inc. | Deamidated interferon-β |
| FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
| JP2008525041A (ja) | 2004-12-22 | 2008-07-17 | ジェネンテック・インコーポレーテッド | 可溶性多膜貫通型タンパク質の産生方法 |
| US20060242012A1 (en) * | 2005-04-22 | 2006-10-26 | Sumit Agarwal | Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest |
| US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| GB2453589A (en) * | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
| EP2225563B1 (en) * | 2007-11-27 | 2015-01-21 | Janssen Diagnostics, LLC | Automated enumeration and characterization of circulating melanoma cells in blood |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| WO2014186364A2 (en) | 2013-05-13 | 2014-11-20 | Tufts University | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer |
| TW201613622A (en) * | 2014-10-14 | 2016-04-16 | Bionet Corp | Composition for skincare and pharmaceutical composition and preparation method thereof |
| TW201613621A (en) * | 2014-10-14 | 2016-04-16 | Bionet Corp | Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof |
| JP2018130113A (ja) * | 2017-02-15 | 2018-08-23 | 国立大学法人 東京大学 | 慢性骨髄性白血病（ｃｍｌ）の検査方法及び検査用キット、チロシンキナーゼ阻害剤（ｔｋｉ）耐性ｃｍｌの単離方法、並びにｃｍｌにおけるｔｋｉ耐性の低減剤及びそのスクリーニング方法 |
| AU2020283906A1 (en) * | 2019-05-31 | 2022-01-20 | Trustees Of Tufts College | Anti-ADAM8 antibodies and uses of the same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04187084A (ja) * | 1990-11-22 | 1992-07-03 | Otsuka Pharmaceut Co Ltd | 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体 |
| ATE165817T1 (de) * | 1994-01-20 | 1998-05-15 | British Biotech Pharm | Metalloproteinaseinhibitoren |
| GB9608130D0 (en) | 1996-04-19 | 1996-06-26 | Univ Sheffield | Adam proteins and uses thereof |
| EP0988056B1 (en) | 1997-01-22 | 2003-07-09 | Board Of Regents, The University Of Texas System | Tissue factor methods and compositions for coagulation and tumor treatment |
| GB9705521D0 (en) * | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
| US5922566A (en) * | 1997-05-13 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Tumor-associated antigen |
| CA2330929A1 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| ATE488529T1 (de) * | 1999-07-28 | 2010-12-15 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| AU4721901A (en) * | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| ATE329060T1 (de) * | 2000-03-24 | 2006-06-15 | Micromet Ag | Mrna amplifizierung |
| US6458552B1 (en) * | 2000-06-06 | 2002-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Metalloprotease peptide substrates and methods |
| WO2002029107A2 (en) * | 2000-10-02 | 2002-04-11 | Board Of Regents, The University Of Texas System | Method of detection and interpretation of mutations through expression or function tests of haploid genes |
| AU2002230997A1 (en) * | 2000-12-15 | 2002-06-24 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| AU2002305193A1 (en) * | 2001-04-18 | 2002-11-05 | Wyeth | Methods and reagents for regulating bone and cartilage formation |
| US20030138792A1 (en) * | 2001-05-31 | 2003-07-24 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
| AU2002318944A1 (en) * | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| US20030148334A1 (en) * | 2001-10-12 | 2003-08-07 | Zairen Sun | Differentially-expressed genes and polypeptides in angiogenesis |
| JP2005532997A (ja) * | 2002-03-01 | 2005-11-04 | チルドレンズ ホスピタル メディカル センター | 喘息またはアレルギーの処置 |
| US20040018522A1 (en) * | 2002-05-09 | 2004-01-29 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with multiple sclerosis |
| US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| JP2004041121A (ja) * | 2002-07-12 | 2004-02-12 | Hitachi Ltd | アレルギー解析方法及びシステム |
| CA2941594C (en) * | 2002-12-20 | 2021-07-06 | Celera Corporation | Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof |
| US8088737B2 (en) * | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| US20050009067A1 (en) * | 2003-05-19 | 2005-01-13 | Craig Logsdon | Expression profile of pancreatic cancer |
| WO2005026325A2 (en) * | 2003-09-10 | 2005-03-24 | Surromed, Inc, | Bivalent targeting of cell surfaces |
-
2000
- 2000-07-27 AT AT00950879T patent/ATE488529T1/de active
- 2000-07-27 EP EP00950879A patent/EP1204682B1/en not_active Expired - Lifetime
- 2000-07-27 WO PCT/US2000/020731 patent/WO2001009189A2/en not_active Ceased
- 2000-07-27 CA CA2378182A patent/CA2378182C/en not_active Expired - Lifetime
- 2000-07-27 DE DE60045247T patent/DE60045247D1/de not_active Expired - Lifetime
- 2000-07-27 JP JP2001513995A patent/JP2003508028A/ja not_active Withdrawn
- 2000-07-27 AU AU63913/00A patent/AU776600B2/en not_active Expired
- 2000-07-27 ES ES00950879T patent/ES2355055T3/es not_active Expired - Lifetime
-
2002
- 2002-08-22 US US10/226,844 patent/US7226596B2/en not_active Expired - Lifetime
-
2007
- 2007-05-25 US US11/754,196 patent/US20080175842A1/en not_active Abandoned
-
2011
- 2011-10-21 JP JP2011231764A patent/JP5897300B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-03 JP JP2014040627A patent/JP2014144959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003508028A5 (enExample) | ||
| Qi et al. | Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma | |
| Gupta et al. | Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen | |
| Ishida et al. | Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome | |
| Yamashita et al. | Activation of hepatic stem cell marker EpCAM by Wnt–β-catenin signaling in hepatocellular carcinoma | |
| Scholler et al. | Soluble member (s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma | |
| Sahin et al. | Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development | |
| Liu et al. | Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer | |
| Takahashi et al. | Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressiveeffect of chemotherapy on the serum endoglin | |
| Ohuchida et al. | The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target | |
| He et al. | Expression of hedgehog pathway components is associated with bladder cancer progression and clinical outcome | |
| JP2007504280A5 (enExample) | ||
| JP6110786B2 (ja) | Ｐｓａの測定方法及びその試薬 | |
| WO2013050453A1 (en) | Oxmif as a diagnostic marker | |
| AU2018364987A1 (en) | Non-coding RNA for detection of cancer | |
| Wang et al. | Identification of an immune-related signature indicating the dedifferentiation of thyroid cells | |
| Zhou et al. | Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance | |
| JP2014530360A5 (enExample) | ||
| Yang et al. | The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma | |
| Luo et al. | Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules | |
| CN119775412A (zh) | 一种抗TNF-α的人源化纳米抗体及其应用 | |
| CN114981453A (zh) | 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定 | |
| Zhang et al. | Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma | |
| Piano et al. | Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma | |
| JP2008500833A5 (enExample) |